Abstract
the Department of Otolaryngology and Communicative rvices, University of Mississippi Medical Center, Jackson, d the Department of Dermatology, University of Rochester hool of Medicine and Dentistry, Rochester. rodell is on the speaker’s bureau for Allergan, Galderma, /Graceway Pharmaceuticals, GlaxoSmithKline/Stiefel, Deric, Novartis Pharmaceuticals Corporation, Sanofi-Aventis, edicis, and PharmaDerm, a division of Nycomed US Inc. He s serves as a consultant for Galderma Laboratories, LP, edicis, Dow Pharmaceuticals Sciences, and Promius; has rved on advisory boards for Dow Pharmaceutical Sciences d Nycomed US Inc, and has received grant/research support from Galderma, Abbott Laboratories, and Dow Pharmaceutical Sciences. None of these disclosures are thought to be relevant conflicts of interest. Ms Shlapak and Dr Ward have no conflicts to disclose. Funding sources: None. Reprint requests: Robert T. Brodell, MD, 2500 N State St, Jackson, MS 39216. E-mail: rbrodell@umc.edu. J Am Acad Dermatol 2013;68:e149-50. 0190-9622/$36.00 a 2012 by the American Academy of Dermatology, Inc. http://dx.doi.org/10.1016/j.jaad.2012.10.029
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
